Document is current
Any future updates will be listed below
-
Authors
Kennedy, Philippa R
Kile, Quinlan M
Waller, Rhett L
Bendzick, Laura
Selleck, Carly
Hinderlie, Peter
Kaufman, Marissa
Kodal, Behiye
Valamehr, Bahram
Miller, Jeffrey S
Felices, Martin
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04023071 at ClinicalTrials.govnct04614636 at ClinicalTrials.govDocuments that mention this clinical trial
365 Oxygen levels found in bone marrow (5%) provide an optimal niche for the differentiation of induced-pluripotent stem cell-derived NK cells for the treatment of AML
https://doi.org/10.1136/jitc-2023-sitc2023.0365
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells
https://doi.org/10.1136/jitc-2022-004693
nct04714372 at ClinicalTrials.govDocuments that mention this clinical trial
365 Oxygen levels found in bone marrow (5%) provide an optimal niche for the differentiation of induced-pluripotent stem cell-derived NK cells for the treatment of AML
https://doi.org/10.1136/jitc-2023-sitc2023.0365
Documents that mention this clinical trial
365 Oxygen levels found in bone marrow (5%) provide an optimal niche for the differentiation of induced-pluripotent stem cell-derived NK cells for the treatment of AML
https://doi.org/10.1136/jitc-2023-sitc2023.0365
- License Information
